Percutaneous microwave ablation of adrenal tumours under ultrasound guidance in 33 patients with 35 tumours: A single-centre experience

Ren, Chao; Liang, Ping; Yu, Xiaoling; Cheng, Zhigang; Han, Zhiyu; Yu, Jie

doi:10.3109/02656736.2016.1164905

Cited by 32 publications

(25 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This rate is comparable to the rates reported in previous studies that used microwave (15.2%) and radiofrequency (23%) ablation. [1,16] Here, the median time to local progression was 17 months, which was within the range reported in prior studies that employed microwave (24 months) and radiofrequency (8.6 months) ablation. [1,16] These results may indicate that cryoablation has a similar effect in local control of adrenal metastases to the thermal ablation methods.…”

Section: Discussionsupporting

confidence: 80%

Computed tomography-guided cryoablation for adrenal metastases: local control and survival

Zhang

Lee

et al. 2018

Medicine

View full text Add to dashboard Cite

To evaluate the feasibility, local control, and survival after computed tomography (CT)-guided cryoablation for adrenal metastases.This study included 31 consecutive patients with adrenal metastases who were treated by CT-guided cryoablation in our center from July 2011 to October 2017. The technical success rate, local progression rate, local progression-free survival (LPFS), systemic progression-free survival (SPFS), and overall survival were assessed. The predictors of survival were determined using univariate and multivariate Cox regression analyses.The primary and secondary technical success rates were 90.3% and 100%, respectively. None of the patients experienced a hypertensive crisis. The local progression rate during follow-up was 19.4%. Systemic progression was found in 9 patients. The cumulative 1-, 3-, and 5-year LPFS rates were 80.6%, 37.8%, and 18.4%, respectively. The cumulative 1-, 3-, and 5-year SPFS rates were 77.4%, 31.9%, and 14.6%, respectively. The cumulative 1-, 3-, and 5-year overall survival rates were 83.9%, 45.0%, and 30.0%, respectively. The existence of an extra-adrenal tumor was a significant independent predictor of worse overall survival (P = .012). The mean overall survival durations were significantly different between patients with and without an extra-adrenal tumor (16.6 ± 2.4 vs 50.9 ± 4.5 months, P <.001).Our findings support that CT-guided cryoablation is a safe and effective method for controlling adrenal metastases and imply that this approach may improve the survival of patients with adrenal metastases.

show abstract

Section: Discussionsupporting

confidence: 80%

Computed tomography-guided cryoablation for adrenal metastases: local control and survival

Zhang

Lee

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…In response to the applied electrical field of microwaves, the rotation of dipole molecules and ionic polarisation produce friction and heat, thus inducing cellular death via coagulation necrosis [15]. This technology has been widely used to treat solid tumours of the liver, spleen, thyroid and other organs [16][17][18][19][20][21][22][23][24]. In 2011, Zhang et al [5] studied PMWA therapy for uterine fibroids and confirmed its safety and efficacy.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of ultrasound-guided percutaneous microwave ablation for symptomatic uterine fibroids: a multicentre study in China

Liu

Zhang

Han

et al. 2016

International Journal of Hyperthermia

Self Cite

View full text Add to dashboard Cite

show abstract

“… 29 2016 31 Retrospective Microwave ablation 77.4% NR by grade Ren et al. 30 2016 20 Retrospective Microwave ablation 84.8% None by SIR Frenk et al. 31 2017 38 Retrospective Radiofrequency, cryoablation, or microwave ablation 1 y 82% 2 y 75% Minor: 6% Major: 12% Botsa et al.…”

Section: Discussionmentioning

confidence: 99%

“… 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 Percutaneous ablative procedures such as microwave and radiofrequency ablation are also frequently used, and several retrospective series have reported 3-year OS rates >50%. 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 A noninvasive, ablative modality called stereotactic body radiation therapy (SBRT; also referred to as stereotactic ablative radiation therapy) has emerged as a promising alternative option for the local treatment of oligometastatic disease. 33 , 34 , 35 Preliminary experience with the use of SBRT to treat adrenal metastases demonstrates low toxicity rates with local disease control that ranges between 55% and 95% at 1 year.…”

Section: Introductionmentioning

confidence: 99%

Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity

Toesca¹,

Koong²,

Eyben³

et al. 2018

Advances in Radiation Oncology

View full text Add to dashboard Cite

PurposeThis study aimed to report on our institutional experience in the use of stereotactic body radiation therapy (SBRT) for the treatment of adrenal gland metastases. Specifically, we examined the outcomes and toxicity from this treatment modality on adjacent organs at risk.Methods and MaterialsData were retrieved from patients with adrenal metastases who were treated with SBRT between 2008 and 2017. Patients with primary adrenal malignancies were excluded. Toxicities were graded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03. Time-to-event rates were calculated from the date of SBRT delivery.ResultsIn total, 35 patients with adrenal metastases were identified. Four patients were treated for bilateral disease. The median dose was 40 Gy (range, 20-54 Gy) in 5 fractions (range, 1-6 fractions). The median follow-up time was 37 months (range, 14-451 months) from disease diagnosis and 7 months (range, 1-54 months) from the SBRT start date. With death treated as a competing risk event, the cumulative incidence of local failure was 7.6% at 1 year after SBRT and 19.2% at 3 years. The median overall survival (OS) time was 19 months (95% confidence interval, 8-54 months) and tumor size correlated with survival (P = .0006). Patients with metastases <2.9 cm had a median OS of 54 months compared with 11 months for those with adrenal metastases ≥2.9 cm (P = .01). Incidence of grade 2 toxicity was 17% with no case of grade ≥3 toxicity. SBRT did not impact renal function with a mean estimated decline in glomerular filtration rate of only 2.6 ± 8 mL/min/1.73 m2 compared with baseline. Combined kidneys V5 and combined renal cortex V17.5 did not correlate with a change in estimated glomerular filtration rate (P = .7 and P = .9, respectively).ConclusionsSBRT offers excellent local control for the treatment of adrenal gland metastases with very low toxicity rates and no significant short-term impact on renal function.

show abstract

Percutaneous microwave ablation of adrenal tumours under ultrasound guidance in 33 patients with 35 tumours: A single-centre experience

Abstract: Percutaneous MWA under US guidance is effective in terms of good local control of adrenal tumours with a diameter of less than or equal to 5 cm and is capable of treating biochemically active tumours harbouring clinical syndromes.

Cited by 32 publications

References 24 publications

Computed tomography-guided cryoablation for adrenal metastases: local control and survival

Computed tomography-guided cryoablation for adrenal metastases: local control and survival

Effectiveness of ultrasound-guided percutaneous microwave ablation for symptomatic uterine fibroids: a multicentre study in China

Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity

Contact Info

Product

Resources

About